Crystallization and preliminary X‐ray crystallographic analysis of the sclerostin‐neutralizing Fab AbD09097. Issue 4 (1st April 2015)

• Record Type: Journal Article
• Authors: Boschert, Verena; Muth, Eva‐Maria; Knappik, Achim; Frisch, Christian; Mueller, Thomas D.
• Is Part Of: Acta crystallographica. Volume 71:Issue 4(2015:Apr.)
• Page Start: 388
• Page End: 392
• Publication Date: 2015-04-01
• Subjects: Crystallography -- Periodicals; Crystals -- Periodicals; 548
• DOI: 10.1107/S2053230X1500360X
• Languages: English
• ISSNs: 2053-230X

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The secreted cystine‐knot protein sclerostin was first identified from genetic screening of patients suffering from the rare bone‐overgrowth diseases sclerosteosis and van Buchem disease. Sclerostin acts a negative regulator of bone growth through inhibiting the canonical Wnt signalling cascade by binding to and blocking the Wnt co‐receptor LRP5/6. Its function in blocking osteoblastogenesis makes it an important target for osteoanabolic therapy approaches to treat osteoporosis, which is characterized by a progressive decrease in bone mass and density. In this work, the production, crystallization and preliminary X‐ray diffraction data analysis of a sclerostin‐neutralizing human Fab antibody fragment, AbD09097, obtained from a naive antibody library are reported. Crystals of the Fab AbD09097 belonged to space group <italic>P</italic>2₁, with unit‐cell parameters <italic>a</italic> = 45.19, <italic>b</italic> = 78.49, <italic>c</italic> = 59.20 Å, β = 95.71° and diffracted X‐rays to a resolution of 1.8 Å.</p> </abstract>